2005PubMedRequires access

CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction.

Wilbert S. Aronow

Open publisher page 17 citations

Abstract

Cardiac resynchronization therapy (CRT) significantly improves functional status, exercise duration, left ventricular (LV) ejection fraction, death from progressive congestive heart failure (CHF), and hospitalization for CHF in patients with moderate-to-severe CHF, an abnormal LV ejection fraction, and a QRS duration on the electrocardiogram of 120 msec or more. In these patients, CRT reduces all-cause mortality, though not significantly. However, CRT plus. an implantable cardioverter-defibrillator (ICD) significantly reduces all-cause mortality. Compared with placebo, ICD therapy significantly reduced all-cause mortality by 33% in patients with class II or III CHF, an abnormal LV ejection fraction, and a QRS duration on the electrocardiogram of 120 msec or more.

About this research paper

What this paper is about

Cardiac resynchronization therapy (CRT) significantly improves functional status, exercise duration, left ventricular (LV) ejection fraction, death from progressive congestive heart failure (CHF), and hospitalization for CHF in patients with moderate-to-severe CHF, an abnormal LV ejection fraction, and a QRS duration on the electrocardiogram of 120 msec or more. In these patients, CRT reduces all-cause mortality, though not significantly. However, CRT plus. an implantable cardioverter-defibrillator (ICD) significantly reduces all-cause mortality. Compared with placebo, ICD therapy significantly reduced all-cause mortality by 33% in patients with class II or III CHF, an abnormal LV ejection fraction, and a QRS duration on the electrocardiogram of 120 msec or more.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Cardiac resynchronization therapy (CRT) significantly improves functional status, exercise duration, left ventricular (LV) ejection fraction, death from progressive congestive heart failure (CHF), and hospitalization for CHF in patients with moderate-to-severe CHF, an abnormal LV ejection fraction, and a QRS duration on the electrocardiogram of 120 msec or more. In these patients, CRT reduces all-cause mortality, though not significantly. However, CRT plus. an implantable cardioverter-defibrillator (ICD) significantly reduces all-cause mortality. Compared with placebo, ICD therapy significantly reduced all-cause mortality by 33% in patients with class II or III CHF, an abnormal LV ejection fraction, and a QRS duration on the electrocardiogram of 120 msec or more.

Key concepts: Medicine, Cardiology, Heart failure, Ejection fraction, Internal medicine, Cardiac resynchronization therapy, QRS complex, Implantable cardioverter-defibrillator

Related papers

Back to paper searchBrowse research topicsOriginal source
CRT plus ICD in congestive heart failure. Use of cardiac resynchronization therapy and an implantable cardioverter-defibrillator in heart failure patients with abnormal left ventricular dysfunction. — Research Paper | ScholarLens